However, the data showed a trend to more irAEs of any severity and irAEs grade ≥ 3 occurring in the age ≥ 75 years group.
← all excerpts
Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer.
1
—
—
However, the data showed a trend to more irAEs of any severity and irAEs grade ≥ 3 occurring in the age ≥ 75 years group.